keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressant augmentation

keyword
https://www.readbyqxmd.com/read/29763645/agmatine-potentiates-neuroprotective-effects-of-subthreshold-concentrations-of-ketamine-via-mtor-s6-kinase-signaling-pathway
#1
Mauren K Tavares, Suellen Dos Reis, Nicolle Platt, Isabella A Heinrich, Ingrid A V Wolin, Rodrigo B Leal, Manuella P Kaster, Ana Lúcia S Rodrigues, Andiara E Freitas
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most robust neurobiological findings in the pathophysiology of major depressive disorder (MDD) over the last 40 years. The persistent increase in glucocorticoids levels induces morphological and anatomical changes in the brain, especially in the hippocampus. Ketamine represents a major advance for the treatment of MDD, however the psychotomimetic effects of this compound limit its widespread use. Agmatine is a neuromodulator that has been shown to be a putative novel and well-tolerated antidepressant/augmenter drug...
May 12, 2018: Neurochemistry International
https://www.readbyqxmd.com/read/29732913/augmentation-strategies-for-clozapine-refractory-schizophrenia-a-systematic-review-and-meta-analysis
#2
Dan J Siskind, Michael Lee, Arul Ravindran, Qichen Zhang, Evelyn Ma, Balaji Motamarri, Steve Kisely
BACKGROUND: Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40% of people will meet response criteria. We therefore undertook a systematic review and meta-analysis of global literature on clozapine augmentation strategies. METHODS: We systematically reviewed PubMed, PsycInfo, Embase, Cochrane Database, Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database for randomised control trials of augmentation strategies for clozapine resistant schizophrenia...
May 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29723763/behavioral-activation-therapy-during-transcranial-magnetic-stimulation-for-major-depressive-disorder
#3
Grace B Russo, Eric Tirrell, Andrew Busch, Linda L Carpenter
BACKGROUND: Behavioral Activation (BA) Therapy and Transcranial Magnetic Stimulation (TMS) have each been shown to be effective in the treatment of adult outpatients with major depressive disorder (MDD). Combining both treatments may produce synergistic antidepressant outcomes. METHODS: We developed a new protocol for incorporating a simplified version of BA during a standard 6-week course of TMS and it was pilot tested in 11 consecutively treated outpatients with treatment resistant depression (TRD)...
April 25, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29692707/vagus-nerve-stimulation-vns-and-other-augmentation-strategies-for-therapy-resistant-depression-trd-review-of-the-evidence-and-clinical-advice-for-use
#4
REVIEW
Helge H O Müller, Sebastian Moeller, Caroline Lücke, Alexandra P Lam, Niclas Braun, Alexandra Philipsen
In addition to electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS) is one of the approved neurostimulation tools for treatment of major depression. VNS is particularly used in therapy-resistant depression (TRD) and exhibits antidepressive and augmentative effects. In long-term treatment, up to two-thirds of patients respond. This mini-review provides a comprehensive overview of augmentation pharmacotherapy and neurostimulation-based treatment strategies, with a special focus on VNS in TRD, and provides practical clinical advice for how to select TRD patients for add-on neurostimulation treatment strategies...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29627920/advances-in-pharmacotherapy-of-late-life-depression
#5
REVIEW
John L Beyer, Kim G Johnson
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures...
April 7, 2018: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29621538/ketamine-and-ketamine-metabolites-as-novel-estrogen-receptor-ligands-induction-of-cytochrome-p450-and-ampa-glutamate-receptor-gene-expression
#6
Ming-Fen Ho, Cristina Correia, James N Ingle, Rima Kaddurah-Daouk, Liewei Wang, Scott H Kaufmann, Richard M Weinshilboum
Major depressive disorder (MDD) is the most common psychiatric illness worldwide, and it displays a striking sex-dependent difference in incidence, with two thirds of MDD patients being women. Ketamine treatment can produce rapid antidepressant effects in MDD patients, effects that are mediated-at least partially-through glutamatergic neurotransmission. Two active metabolites of ketamine, (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-HNK, also appear to play a key role in ketamine's rapid antidepressant effects through the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors...
April 2, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29602660/management-of-treatment-failure-in-restless-legs-syndrome-willis-ekbom-disease
#7
REVIEW
Diego Garcia-Borreguero, Irene Cano-Pumarega, Rafael Marulanda
Dopaminergic drugs have been widely used over the last decades for the treatment of restless legs syndrome (RLS)/Willis-Ekbom disease (WED). While the majority of studies show an initial improvement in symptoms, longer studies and clinical experience show that either treatment efficacy decreases with time, and/or augmentation develops: dopaminergic augmentation has been reported to be the main reason for treatment discontinuation and treatment failure in RLS/WED. The current review discusses the main reasons for treatment failure in RLS/WED and outlines the most recent expert-based strategies to prevent and manage it...
January 9, 2018: Sleep Medicine Reviews
https://www.readbyqxmd.com/read/29577229/comparison-of-guidelines-for-the-treatment-of-unipolar-depression-a-focus-on-pharmacotherapy-and-neurostimulation
#8
REVIEW
A J Bayes, G B Parker
OBJECTIVE: To determine the level of agreement across a set of evidence-based guidelines for management of the unipolar depressive disorders and with a focus on physical treatments. METHOD: A literature search was undertaken using the terms 'depression', 'depressive' and 'guidelines', using PubMed, Cochrane Database of Systematic Reviews and the National Guideline Clearinghouse. Twelve national psychiatric or professional guideline-producing organizations were identified from the period 2007-2017, with guidelines qualitatively reviewed by two assessors...
March 25, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29573854/nitric-oxide-involvement-in-additive-antidepressant-like-effect-of-agmatine-and-lithium-in-mice-forced-swim-test
#9
Sattar Ostadhadi, Abbas Norouzi-Javidan, Vahid Nikoui, Samira Zolfaghari, Abouzar Moradi, Ahmad Reza Dehpour
Lithium is still the main agent in the management of mood disorders such as depression. Likewise, agmatine protects the central nervous system (CNS) against depression. The aim of the present study was to examine the possible additive antidepressant-like effect of agmatine and lithium in mice forced swim test (FST) as well as exploration of the probable involvement of nitric oxide (NO) pathway in this response. Results showed that pretreatment with a subeffective dose of agmatine (0.01 mg/kg) augmented the antidepressant-like effect of lithium subeffective dose (3 mg/kg) (P < 0...
March 15, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29567680/chronic-intake-of-the-selective-serotonin-reuptake-inhibitor-fluoxetine-enhances-atherosclerosis
#10
Martina Rami, Raquel Guillamat-Prats, Petteri Rinne, Melanie Salvermoser, Larisa Ring, Mariaelvy Bianchini, Xavier Blanchet, Remco T A Megens, Yvonne Döring, Barbara Walzog, Oliver Soehnlein, Christian Weber, Alexander Faussner, Sabine Steffens
OBJECTIVE: Cardiovascular diseases and depression are the leading causes of disability in Western countries. Clinical data on potential cardiovascular effects of serotonin reuptake inhibitors (SSRIs), the most commonly used antidepressant drugs, are controversial. In addition to blocking serotonin reuptake transporter in the brain, SSRIs deplete the major peripheral serotonin (5-hydroxytryptamine [5-HT]) storage by inhibiting serotonin reuptake transporter-mediated uptake in platelets...
March 22, 2018: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/29559781/novel-treatment-options-in-depression-and-psychosis
#11
REVIEW
Eva Ceskova, Petr Silhan
In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29554535/plasma-c-reactive-protein-levels-in-bipolar-depression-during-cyclooxygenase-2-inhibitor-combination-treatment
#12
David Edberg, Debra Hoppensteadt, Amanda Walborn, Jawed Fareed, James Sinacore, Angelos Halaris
Immune system activation and neuroinflammation appear to play a key role in the pathophysiology and treatment of bipolar depression (BDD). This study is the first to analyze blood levels of the pro-inflammatory biomarker C-reactive protein (CRP) in bipolar disorder patients treated with the cyclooxygenase-2 inhibitor, celecoxib (CBX). In this double-blind study, 47 consenting patients with BDD were randomized to receive either escitalopram (10 mg twice/day) + CBX (200 mg twice/day), or escitalopram (10 mg twice/day) + placebo (twice/day)...
February 13, 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29499033/is-augmentation-with-folate-effective-for-major-depressive-disorder
#13
Javier Trincado, Constanza Caneo
INTRODUCTION: Antidepressant treatment does not lead to a satisfactory response in a significant proportion of patients with depression. It has been postulated that co-administration of pharmacologically standardized nutrients (nutraceuticals), such as folate, would potentiate the effect of antidepressants. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others...
February 25, 2018: Medwave
https://www.readbyqxmd.com/read/29497300/drug-drug-interactions-involving-antidepressants-focus-on-desvenlafaxine
#14
REVIEW
Yvette Low, Sajita Setia, Graca Lima
Psychiatric and physical conditions often coexist, and there is robust evidence that associates the frequency of depression with single and multiple physical conditions. More than half of patients with depression may have at least one chronic physical condition. Therefore, antidepressants are often used in cotherapy with other medications for the management of both psychiatric and chronic physical illnesses. The risk of drug-drug interactions (DDIs) is augmented by complex polypharmacy regimens and extended periods of treatment required, of which possible outcomes range from tolerability issues to lack of efficacy and serious adverse events...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29492960/clinical-correlates-of-augmentation-combination-treatment-strategies-in-major-depressive-disorder
#15
M Dold, L Bartova, J Mendlewicz, D Souery, A Serretti, S Porcelli, J Zohar, S Montgomery, S Kasper
OBJECTIVE: This multicenter, multinational, cross-sectional study aimed to investigate clinical characteristics and treatment outcomes associated with augmentation/combination treatment strategies in major depressive disorder (MDD). METHOD: Sociodemographic, clinical, and treatment features of 1410 adult MDD patients were compared between MDD patients treated with monotherapy and augmentation/combination medication using descriptive statistics, analyses of covariance (ancova), and Spearman's correlation analyses...
May 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29488218/ebselen-has-lithium-like-effects-on-central-5-ht-2a-receptor-function
#16
I Antoniadou, M Kouskou, T Arsiwala, N Singh, S R Vasudevan, T Fowler, E Cadirci, G C Churchill, T Sharp
BACKGROUND AND PURPOSE: Lithium's antidepressant action may be mediated by inhibition of inositol monophosphatase (IMPase), a key enzyme in Gq protein coupled receptor signalling. Recently, the antioxidant agent ebselen was identified as an IMPase inhibitor. Here we investigated both ebselen and lithium in models of the 5-HT2A receptor, a Gq protein coupled receptor implicated in lithium's actions. EXPERIMENTAL APPROACH: 5-HT2A receptor function was modelled in mice by measuring the behavioural (head-twitches) and cortical immediate early gene (IEG; Arc, c-fos and Erg2 mRNA) responses to 5-HT2A receptor agonist administration...
February 27, 2018: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29486867/rostral-anterior-cingulate-cortex-morphology-predicts-treatment-response-to-internet-based-cognitive-behavioral-therapy-for-depression
#17
Christian A Webb, Elizabeth A Olson, William D S Killgore, Diego A Pizzagalli, Scott L Rauch, Isabelle M Rosso
BACKGROUND: Rostral and subgenual anterior cingulate cortex (rACC and sgACC) activity and, to a lesser extent, volume have been shown to predict depressive symptom improvement across different antidepressant treatments. This study extends prior work by examining whether rACC and/or sgACC morphology predicts treatment response to Internet-based cognitive behavioral therapy (iCBT) for major depressive disorder. This is the first study to examine neural predictors of response to iCBT. METHODS: Hierarchical linear modeling tested whether pretreatment rACC and sgACC volumes predicted depressive symptom improvement during a six-session (10-week) randomized clinical trial of iCBT (n = 35) versus a monitored attention control condition (n = 38)...
March 2018: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://www.readbyqxmd.com/read/29485948/prospective-service-use-and-health-care-costs-of-medicaid-beneficiaries-with-treatment-resistant-depression
#18
Mark Olfson, Tony B Amos, Carmela Benson, Jacquelyn McRae, Steven C Marcus
BACKGROUND: Although the clinical and health economic characteristics of commercially insured adults with treatment-resistant depression (TRD) have been well characterized, little is known about TRD in the Medicaid population. OBJECTIVE: To describe clinical and health economic characteristics of adult Medicaid beneficiaries with TRD. METHODS: Retrospective longitudinal cohort analyses were performed with Truven Health MarketScan Medicaid Database (2008-2014), focusing on adults with major depressive disorder (MDD) following an index antidepressant prescription...
March 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29442609/caveat-emptor-folate-in-unipolar-depressive-illness-a-systematic-review-and-meta-analysis
#19
Emmert Roberts, Ben Carter, Allan H Young
BACKGROUND: International guideline recommendations for the use of folate and its derivatives in the treatment of unipolar depressive disorders are confused and contradictory, perhaps reflecting wide variations in the underpinning evidence base. INTRODUCTION: We discuss differing methods of evidence synthesis in the formulation of international guideline recommendations. As an example we evaluated the efficacy of folate and its derivatives in unipolar depression via systematic review and meta-analysis...
April 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29431197/efficacy-and-safety-of-antidepressant-augmentation-of-continued-antipsychotic-treatment-in-patients-with-schizophrenia
#20
B Galling, J A Vernon, A K Pagsberg, A Wadhwa, E Grudnikoff, A J Seidman, M Tsoy-Podosenin, M Poyurovsky, J M Kane, C U Correll
OBJECTIVE: To evaluate the efficacy and safety of antidepressant augmentation of antipsychotics in schizophrenia. METHODS: Systematic literature search (PubMed/MEDLINE/PsycINFO/Cochrane Library) from database inception until 10/10/2017 for randomized, double-blind, efficacy-focused trials comparing adjunctive antidepressants vs. placebo in schizophrenia. RESULTS: In a random-effects meta-analysis (studies = 42, n = 1934, duration = 10...
March 2018: Acta Psychiatrica Scandinavica
keyword
keyword
86292
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"